Another Potential Test for Prostate Cancer

I recently came across an article on a new type of molecular test that can evaluate the likelihood of a patient having clinically significant prostate cancer – in advance of a biopsy.

The new novel blood test is called IsoPSA. It was developed in partnership with the Cleveland Clinic and granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). The test can be used in conjunction with a standard PSA test and may allow a patient to avoid an unnecessary painful test and aftermath.

Going through a biopsy

Historically physicians have used standard PSA blood testing to look for levels of 4 nanograms per milliliter or higher as a baseline for recommending a prostate biopsy. Having been personally through a prostate biopsy, I can confirm that depending upon the individual doing the testing, the biopsy target areas, and your personal tolerance levels, the reactions can vary significantly.

I have spoken with many men who have experienced prostate biopsy testing. Some report little discomfort, while others expressed a great deal of concern over the testing process. Several asked to be “knocked out” when they faced the possibility of a second test. Unfortunately, none of us know how we will react in advance.

Should you need to undergo a biopsy, I think it's good to find a urologist who has done extensive previous testing and can confirm the use of a locally-applied anesthesia as part of the process.

What the IsoPSA test can do

This new IsoPSA blood test is generally used for men ages 50 and over with an elevated PSA level.1 The test can help both patient and physician decide on whether a biopsy should be performed. It does not just look at the amount of PSA in a person's bloodstream, but also at changes in the PSA protein. If an elevated PSA is found, the IsoPSA test can identify the molecular changes that are produced by cancerous and/or benign cells.

The new IsoPSA test is among newer tests that augment PSA testing and may help determine a man's risk of having significant prostate cancer.

Below the belt issues

One of the "below the belt" issues men can face with advancing age is a condition called benign prostatic hyperplasia (BPH). This is basically a swollen prostate that can over time restrict or block urine flow. To relieve pressure, physicians may prescribe drugs that can decrease the swelling. While able to relieve pressure, the drugs can also affect PSA levels.

The resulting reduction in PSA levels can provide misleading information to the physician who is trying to evaluate next steps in a patient’s treatment plan. The hope with the IsoPSA test is that it's not as impacted by medications that treat BPH.

Whether the test is available

The Cleveland Clinic suggests that the new test can be transformative in that it can be more accurate and specific then PSA testing alone.

But because the test is so new, patients may not be covered by Medicare or Medicaid and some insurance companies, and physicians may not be aware of it. Where it's available may also play a role. As of earlier this year, the test had mainly been offered at the Cleveland Clinic.

By providing your email address, you are agreeing to our privacy policy. We never sell or share your email address.

More on this topic

This article represents the opinions, thoughts, and experiences of the author; none of this content has been paid for by any advertiser. The ProstateCancer.net team does not recommend or endorse any products or treatments discussed herein. Learn more about how we maintain editorial integrity here.

Join the conversation

or create an account to comment.